ClinicalTrials.gg
CompletedNCT00047580Updated Dec 14, 2015

Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.

A Phase 3 interventional study of tizanidine hydrochloride capsule in Multiple Sclerosis, Muscle Spasticity and Spinal Cord Injury, sponsored by Elan Pharmaceuticals. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-14.

Sponsored by Elan Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Enrollment
227th of 879
120 · median 50
Started
2002
with 11 others
Phase 3
127 of 1,192
8 open now
Registered
21st of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 227th largest by enrollment of the 879 interventional ones that give a count, is one of 12 that started in 2002, is one of 127 in phase 3, and was the 21st registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to compare the impact of somnolence (sleepiness) on cognition (awareness) as well as the safety and effectiveness of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride tablets) taken while in the fed state (just after a meal) and in the fasted state (before a meal) in patients with moderate to severe spasticity.

03

Conditions studied

  • Multiple Sclerosis
  • Muscle Spasticity
  • Spinal Cord Injury
  • Stroke

Keywords

  • Spasticity
  • spasticity secondary to Multiple Sclerosis
  • Spinal Cord Injury
  • Stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • IRB approved ICF must be signed and dated by patient or patient's legal representative
  • Male or Female 18 years of age or older
  • Clinical diagnosis of established spasticity (at least 3 months) secondary to multiple sclerosis, stroke, or spinal cord injury
  • Currently on stable dose of up to 36mg of Zanaflex
  • Must be able to swallow tablets or capsules whole

Exclusion criteria

Exclusion Criteria:

  • Patients with dementia, aphasia, or other deficits in cognition
  • Unwilling or unable to complete cognition test or daily diary
  • Known sensitivity to Zanaflex
  • Taking Zanaflex on an as needed ("prn") basis
  • Currently being treated with drugs having significant effects at the alpha2 receptors whether agonist (i.e., clonidine, methyldopa) or antagonist (i.e., phenothiazines, imipramine)
  • Currently on any other muscle relaxant or any drugs having muscle relaxant properties (including baclofen, dantrolene, diazepam and other benzodiazepines, tranquilizers, narcotic analgesics, high dose neuroleptics, chlormezanone, meprobamate, methocarbamol, orphenadrine, carisoprodol, gabapentin and clonidine
  • Taking any over-the-counter or prescription sleep aids within 30 days prior to screening
  • Use of illegal drugs or legal drugs for recreational purposes or excessive use of alcohol
  • Patients suffering from disabling, symptomatic hypotension (i.e., syncope)
  • Patients having any systemic disease such as renal insufficiency, elevations in hepatic transaminase, severe, uncontrolled systemic hypertension
  • Any clinically significant illnesses, within four weeks of screening
  • Patients with known sleep disorders
  • Patients who participated in a clinical trial within thiry days prior to screening
  • Women of who are pregnant, have a positive serum pregnancy test, lactating, or do not or will not take adequate precautions for the duration of trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Masking
None (open label)
Enrollment
120 participants
06

Study locations

16 sites
  • Radiant Research
    Tucson, Arizona 85710, United States
  • The Neurology Center
    Encinitas, California 92024, United States
  • Northridge Neurological Center
    Northridge, California 91325, United States
  • The Neurology Center
    Oceanside, California 92056, United States
  • Neurology Medical Group of Diablo Valley
    Walnut Creek, California 94598, United States
  • Colorado Neurology Movement Disorders Center
    Englewood, Colorado 80110, United States
  • Yale Center for MS Treatment and Research
    New Haven, Connecticut 06510, United States
  • Neurology Clinic Research Institution
    Plantation, Florida 33324, United States
  • Axiom Clinical Research
    Tampa, Florida 33609, United States
  • Comprehensive Neurology Specialists, PC
    Atlanta, Georgia 30338, United States
  • Neurotrials Research, Inc.
    Atlanta, Georgia 30342, United States
  • Springfield Clinic Neuroscience Institute
    Springfield, Illinois 62702, United States
  • The Minneapolis Clinic of Neurology, Ltd.
    Minneapolis, Minnesota 55422, United States
  • Neurological Associates of Tulsa, Inc.
    Tulsa, Oklahoma 74136-8327, United States
  • Medford Neurological and Spine Clinic
    Medford, Oregon 97504-8456, United States
  • Sargent Rehabilitation Center
    Warwick, Rhode Island 02818, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002 and a completion of Sep 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2002
First posted
Oct 10, 2002
Start
Jun 2002
Completion
Sep 2002
Last update
Dec 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Dec 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00047580
Lead sponsor
Elan Pharmaceuticals
First posted
Oct 10, 2002
Start date
Jun 2002
Completion
Sep 2002
Last update
Dec 14, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tizanidine

Start the discussion